secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001746473-23-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant reports Q4 2022 net loss $35.1M; positive bexotegrast data, $287.5M raise extends runway to H2 2026
--------------------------------------------------------------------------------

- Bexotegrast 320 mg in IPF Phase 2a showed statistically significant FVC increases at 12 weeks; no drug-related severe AEs.
- Closed $287.5M equity offering in Jan 2023; net proceeds $269.9M, extending cash runway into second half of 2026.
- Q4 2022 net loss $35.1M ($24.5M prior year); R&D expenses $25.1M, G&A $14.3M.
- 24-week INTEGRIS-IPF 320 mg data expected Q2 2023; Phase 2b IPF trial initiation mid-2023.
- EMA granted Orphan Drug designation for bexotegrast in IPF; Novartis terminated PLN-1474 deal and returned rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647323000007/0001746473-23-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647323000007/plrx-20230309.htm
  HTML page:      https://secwatch.observer/filing/0001746473-23-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer